Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

Haematologica. 2024 Feb 1;109(2):676-681. doi: 10.3324/haematol.2023.283106.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Letter

MeSH terms

  • Benzamides*
  • Humans
  • Janus Kinase 2 / genetics
  • Nitriles
  • Primary Myelofibrosis* / chemically induced
  • Primary Myelofibrosis* / drug therapy
  • Pyrazoles*
  • Pyrimidines / adverse effects

Substances

  • ruxolitinib
  • N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
  • Pyrimidines
  • Nitriles
  • Janus Kinase 2
  • Benzamides
  • Pyrazoles

Grants and funding

Funding: This study was sponsored by Sierra Oncology, a GSK company.